Grep · sample report

Drug Safety & Shortage Watch — Each run checks every drug on your list for new safety communications, label changes, recalls and shortages, with expected return dates, listed alternatives and sources.

workbatch loopweeklyoperational
Inputs used for this sample
The latest edition of Drug Safety & Shortage Watch

Drugs or drug classes to watch (one per line): amoxicillin
semaglutide
methylphenidate
GLP-1 receptor agonists

Country or regulator: United States

Care setting or patient group (optional): Pediatric outpatient clinic

Drug Safety & Shortage Watch, US Pediatric Outpatient: Three Drug Rows in Active Shortage (29 Sep to 6 Oct 2026)

Interpretation: Regulator is the US FDA, with ASHP as the second shortage list. Window is 29 September to 6 October 2026. "GLP-1 receptor agonists" is expanded to agents seen on the FDA and ASHP lists (liraglutide, dulaglutide, semaglutide, tirzepatide, exenatide). Pediatric flags are marked [pediatric]. Brand names were not supplied, so no brand-to-generic mapping was needed.

Rows needing action: 3 of 4 supplied rows (amoxicillin, methylphenidate, GLP-1 class via liraglutide). The FDA Drug Safety Communications page I read was current only to 15 September 2026 and the recall list only to 1 October 2026, so neither covers the whole window; no listed drug appeared on either.

Act on this week

Status by listed drug

Drug Status What changed Date Expected resupply date Listed alternatives Source link
Amoxicillin (oral suspension, chewable, capsule, tablet) shortage ASHP bulletin: Teva discontinuing its beta-lactam line after plant sale to Chartwell; other makers listed as available. [pediatric] ASHP covers all oral forms, including suspension and chewables; it does not single out pediatric forms. 28 Sep 2026 (ASHP update) Not stated for the shortage; Teva stock available until depleted FDA beta-lactam compounding guidance and an American Academy of Pediatrics antibiotic-options resource, as named by ASHP ASHP amoxicillin oral
Methylphenidate (ER tablets, ER capsules and other ER oral forms, IR tablets) shortage FDA list: Lannett ER 27 mg and 36 mg unavailable; Sun ER tablets not marketed. ASHP: Amneal ER (CD) capsules and IR 5 mg and 10 mg on back order with no release estimate. [pediatric] FDA reverification 1 Oct 2026; ASHP updates 13 Aug 2026 Lannett 27/36 mg: November 2026; Amneal: no estimate ASHP names available products (for example Sandoz ER (LA) capsules, Neos ODT); no regulator-named substitution FDA ER tablet entry; ASHP ER oral; ASHP IR tablets
GLP-1 RAs (class) shortage Class row stays open because liraglutide is on the FDA shortage list; sub-rows below. See sub-rows See sub-rows See sub-rows See sub-rows
Class – liraglutide shortage Victoza on limited availability (shipping delay); Saxenda to be discontinued January 2027; Hikma and Meitheal supply listed available on the FDA page. FDA reverified 22 Sep 2026 (Novo); ASHP update 26 Aug 2026 ASHP: Teva 2-count pens late October 2026 and Victoza cannot be estimated (the FDA page lists Teva pens as available, a conflict between lists) ASHP liraglutide bulletin lists none; no pediatric guidance given FDA liraglutide; ASHP liraglutide
Class – dulaglutide no change in window ASHP bulletin lists Trulicity as available, with local pharmacy access still variable. Last updated before the window. 24 Sep 2026 Not stated as a date; bulletin says doses are available but pharmacy access varies by location ADA-based text in the ASHP bulletin names tirzepatide, semaglutide and high-dose dulaglutide (adult type 2 diabetes context) ASHP dulaglutide
Class – semaglutide tablet (FDA list) shortage list entry: discontinuation Semaglutide Tablet appears under FDA "Discontinuation"; notice date and scope not captured. not found n/a not found FDA shortage database
Class – tirzepatide, exenatide, lixisenatide unchecked Only ASHP bulletin dates were seen (tirzepatide Mar 2025, exenatide Feb 2025), none in window; no label, recall or FDA shortage detail was opened. not found not found not found ASHP shortage list
Semaglutide (injection and oral, DailyMed only) no change No in-window SPL posting; shortage status for injection not checked (ASHP has an older bulletin updated 5 Mar 2025). Latest SPL 19 Aug 2026 n/a n/a DailyMed semaglutide SPL list

Notes

Do next

  1. Confirm local wholesaler stock of amoxicillin oral suspension and chewables by strength against the ASHP-listed makers.
  2. Check which methylphenidate ER strengths and brands your pharmacy partners can fill before November 2026.
  3. Open the FDA entry for Semaglutide Tablet to read the discontinuation date and scope.
  4. Read DailyMed labels for tirzepatide, exenatide and dulaglutide for any September 2026 revision.
  5. Open FDA MedWatch and the FDA enforcement report to close the recall check.

Coverage

Not reached or not opened: ASHP and FDA pages for tirzepatide, exenatide and lixisenatide; MedWatch; FDA enforcement reports; page 2 of DailyMed methylphenidate and amoxicillin results (amoxicillin 637 entries over 7 pages; methylphenidate 101 over 2 pages); the FDA shortage entry for amoxicillin (not seen on list). The ASHP site returned 403 to direct fetch; ASHP bulletin pages were read through a scraping fallback.

Sources